Navigation Links
Statin Alternative Looks Promising in Early Trials
Date:3/21/2012

By Maureen Salamon
HealthDay Reporter

WEDNESDAY, March 21 (HealthDay News) -- A new anti-cholesterol drug appears safe and effective in people already taking statins such as Lipitor, making it a potential addition to statin therapy or an alternative, a preliminary new study suggests.

Two single-dose trials in healthy volunteers and a multiple-dose trial in a group with high cholesterol showed that the drug, known as a monoclonal antibody, reduced low-density lipoprotein (LDL, or "bad") cholesterol levels an average of 40 percent. The injectable drug was also well-tolerated by all participants, with headache the most commonly reported side effect.

The drug works by attacking a destructive enzyme in the liver, keeping LDL cholesterol from spilling into the bloodstream, according to the report published in the March 22 issue of the New England Journal of Medicine.

"It was entirely safe, as best they could tell, and LDL levels plummeted within a matter of a few days and remained low for three months," said Dr. Kirk Garratt, clinical director of interventional cardiovascular research at Lenox Hill Hospital in New York City, who was not involved in the study. "If this antibody turns out to be as safe and effective as it appears, this may very well be a very important method for controlling LDL cholesterol, particularly in patients with [drug-resistant] cases."

The study, by Dr. Evan Stein, of the Metabolic and Atherosclerosis Research Center in Cincinnati, and colleagues, was funded by Sanofi and Regeneron Pharmaceuticals -- makers of the antibody.

About one in four Americans aged 45 and older takes statins, which interfere with the production of cholesterol in the liver, to control their high cholesterol levels and improve their odds against heart disease, according to the U.S. Centers for Disease Control and Prevention. While widely effective, some patients experience intolerable side effects -- which include liver damage or muscle pain -- and others don't achieve the recommended LDL blood levels of 70 milligrams (mg) per deciliter or lower for those at risk of heart disease.

Two randomized, single-dose studies of the antibody, known as REGN727, were administered either intravenously (in 40 participants) or by injection (in 32 participants) and compared with a group given an inactive placebo. These trials were followed by a randomized study of multiple doses in 51 adults with high cholesterol who were taking atorvastatin (brand name Lipitor) and whose baseline LDL levels were more than 100 mg per deciliter.

Higher doses of REGN727 lowered LDL cholesterol levels by up to 64 percent, and the effect was similar across the board whether or not participants were also taking a statin, which works by a different mechanism.

Commenting on the study, Christine Metz, head of the Laboratory of Medicinal Biochemistry at the Feinstein Institute for Medical Research in Manhasset, N.Y., said, "The next step would be to test a much larger group of people for a much longer time. But this is very promising, apparently safe under the conditions used, and worth very quickly going forward."

Garratt noted that the new drug, which could take at least several years to reach the market, would need to be injected, since antibodies typically can't be formulated into pills. Such a compound would likely be extremely expensive, especially when compared to statins, which are now available as generic drugs. Also, like statins, such a drug would probably need to be taken for life, he said.

Metz pointed out that the trials were very small and consisted heavily of men, making it hard to generalize results for a broader population.

However, "I thought the study was very beautifully conceived and well done," she added. "It did everything it set out to do."

More information

The U.S. National Library of Medicine has more information about statins.

SOURCES: Kirk Garratt, M.D., clinical director, interventional cardiovascular research, Lenox Hill Hospital, New York City; Christine Metz, Ph.D., head of the Laboratory of Medicinal Biochemistry, Feinstein Institute for Medical Research, Manhasset, N.Y.; March 22, 2012, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Small Increase in Diabetes Risk Noted in Statin Patients
2. Statins May Benefit Prostate Cancer Patients
3. Alternative to Statins Shows Promise
4. Statins may slow progression of multiple sclerosis, new study finds
5. Statins May Slow Progression of Multiple Sclerosis, New Study Finds
6. Do Statins Lower Male Sex Drive?
7. Statins Wont Lower Colon Cancer Risk
8. Statins decrease risk of clot-related diseases
9. Statin Use Tied to Eye, Kidney, Liver Troubles
10. Some statins have unintended effects and warrant closer monitoring, study finds
11. Too Many Stroke Patients Go Without Statins
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Statin Alternative Looks Promising in Early Trials
(Date:2/21/2017)... ... February 21, 2017 , ... ... Medical Clinic in Durant, Oklahoma, on Feb. 21. , The celebration began with ... community members, clinic employees, the construction team and tribal leadership. , Choctaw ...
(Date:2/21/2017)... ... February 21, 2017 , ... Doctors on Liens has announced the addition ... Kendell Mendonca , to its growing network of doctors in Central and Northern California. ... car accidents such as whiplash, back pain, neck pain, hip and knee pain, and ...
(Date:2/21/2017)... Fort Worth, TX (PRWEB) , ... February 21, 2017 , ... ... planning assistance to communities in and around Tarrant County, is embarking on a six ... to research cures and treatments for cancer. , Cancer is one of the deadliest ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... today announced the further expansion of its eHealth App xChange™, providing clinical ... part of Bioclinica’s extensive and growing eHealth platform. Applications that enable patient-centered ...
(Date:2/21/2017)... ... February 21, 2017 , ... HIMSS is ... connected care demonstration spanned multiple health information systems including OpenEMR, EMRDirect, and ... providers have no Health Information Exchange outside of faxing. Medal’s innovative technology “meets ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Diabetic Shoes Market: Overview Read the ... ... disease, which is marked by high levels of blood glucose ... disease has become a global epidemic leading to serious complications ... of the body including eyes, kidneys, heart. However, it has ...
(Date:2/21/2017)... Feb. 21, 2017  Global health services company Cigna ... ® for breast reconstruction surgery and Dermacell ... an advanced acellular dermal matrix developed by LifeNet Health ... NVDQ ) "We are proud ... health-care payers to review the growing base of evidentiary ...
(Date:2/21/2017)... Feb. 21, 2017 ... a new imaging solution that connects Lexmark multifunction printers ... of the world,s leading scanning and indexing software solutions ... enables hospitals to use a Lexmark MFP at the ... Solarity workflow, helping facilities reach HIMSS Stage 7 ...
Breaking Medicine Technology: